8 February 2021 - This milestone makes esketamine nasal spray the first N-methyl-D-aspartate antagonist to be approved for patients with major depressive disorder in a psychiatric emergency.

Janssen announced today that the European Commission has authorised the expanded use of Sparvato (esketamine nasal spray), co-administered with oral antidepressant therapy in adults with a moderate to severe episode of major depressive disorder, as acute short term treatment, for the rapid reduction of depressive symptoms, which according to clinical judgement constitute a psychiatric emergency.

Read Janssen press release